

Bioverativ Inc.  
Form SC TO-C  
January 22, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE TO**  
**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)**  
**of the Securities Exchange Act of 1934**

**Bioverativ Inc**  
**(Name of Subject Company)**  
**BLINK ACQUISITION CORP.**  
**SANOFI-AVENTIS NA HOLDING, INC.**  
**SANOFI-AVENTIS AMERIQUE DU NORD SAS**  
**SANOFI**  
**(Names of Filing Persons Offerors)**  
**Common Stock, Par Value \$0.001 Per Share**  
**(Title of Class of Securities)**

**09075E100**

Edgar Filing: Bioverativ Inc. - Form SC TO-C

(Cusip Number of Class of Securities)

**Karen Linehan**

**Executive Vice President Legal Affairs and General Counsel**

**Sanofi**

**54, Rue La Boétie, 75008**

**Paris, France**

**Telephone: 011 + 33 1 53 77 40 00**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)**

*Copies to:*

**Michael J. Aiello, Esq.**

**Sachin Kohli, Esq.**

**Weil, Gotshal & Manges LLP**

**767 Fifth Avenue**

**New York, NY 10153**

**(212) 310-8000**

#### **CALCULATION OF FILING FEE**

**Transaction Valuation\***

N/A

**Amount of Filing Fee\***

N/A

\* A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.

Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Edgar Filing: Bioverativ Inc. - Form SC TO-C

Amount Previously Paid: Not applicable.  
Form or Registration No.: Not applicable.

Filing Party: Not applicable.  
Date Filed: Not applicable.

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third-party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Joint press release issued by Sanofi and Bioverativ Inc on January 22, 2018.
99.2	Investor presentation dated as of January 22, 2018.
99.3	Email to Bioverativ Inc employees, dated January 22, 2018.
99.4	Email to Sanofi employees, dated January 22, 2018
99.5	Social media content issued by Sanofi on January 22, 2018.